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DNA mismatch repair is an important mechanism in-
volved in maintaining the fidelity of genomic DNA. Defec-
tive DNA mismatch repair is implicated in a variety of
gastrointestinal and other tumors; however, its role in
hepatocellular carcinoma (HCC) has not been assessed.
Formalin-fixed, paraffin-embedded archival pathology tis-
sues from 46 primary liver tumors were studied by microdis-
section and microsatellite analysis of extracted DNA to
assess the degree of microsatellite instability, a marker of
defective mismatch repair, and to determine the extent and
timing of allelic loss of two DNA mismatch repair genes,
human Mut S homologue-2 (hMSH2) and human Mut L
homologue-1 (hMLH1), and the tumor suppressor genes
adenomatous polyposis coli gene (APC), p53, and DPC4.
Microsatellite instability was detected in 16 of the tumors
(34.8%). Loss of heterozygosity at microsatellites linked to
the DNA mismatch repair genes, hMSH2 and/or hMLH1,
was found in 9 cases (19.6%), usually in association with
microsatellite instability. Importantly, the pattern of allelic
loss was uniform in 8 of these 9 tumors, suggesting that
clonal loss had occurred. Moreover, loss at these loci also
occurred in nonmalignant tissue adjacent to 4 of these
tumors, where it was associated with marked allelic hetero-
geneity. There was relatively infrequent loss of APC, p53, or
DPC4 loci that appeared unrelated to loss of hMSH2 or
hMLH1 gene loci. Loss of heterozygosity at hMSH2 and/or
hMLH1 gene loci, and the associated microsatellite instabil-
ity in premalignant hepatic tissues suggests a possible
causal role in hepatic carcinogenesis in a subset of hepato-
mas. (HEPATOLOGY 1998;28:90-97.)
Hepatocellular cancer (HCC) is a major cause of cancer-
related deaths worldwide.1 Outside areas with significant
dietary exposure to aflatoxin B1, the genetic events in hepatic
carcinogenesis are poorly understood. Recently, there has
been interest in the role of DNA mismatch repair system in a
variety of sporadic malignancies and the familial cancer
syndrome, hereditary nonpolyposis colon cancer.2-11 The
DNA mismatch repair system is a group of proteins that
repair short DNA heteroduplex loops and nucleotide base
mismatches that occur during DNA synthesis.12-14 Of the
mismatch repair genes, human Mut S homologue-2 (hMSH2)
and human Mut L homologue-1 (hMLH1) are most fre-
quently affected by germline mutations in hereditary nonpol-
yposis colon cancer.15 There is evidence that the functional
capacity of both alleles of hMLH1 or hMSH2 in a cell must be
lost to inactivate mismatch repair.7,16-18 This is similar to the
mechanism seen with classic tumor suppressor genes such as
adenomatous polyposis coli gene (APC), p53, and DPC4,
which play a key role in colorectal carcinogenesis and are
inactivated by either loss of the region of the chromosome
carrying the gene, referred to as loss of heterozygosity (LOH)
and/or by mutations.19
Short variable number tandem repeats called microsatel-
lites are pleomorphic oligonucleotide (,6 bp) repeat se-
quences found throughout the genome. A common microsat-
ellite repeat motif is [CA], and there are estimated to be
100,000 CA microsatellites scattered throughout the human
genome.20,21 The number of repeats in a microsatellite varies,
and alleles of differing size are stably inherited characteris-
tics. Additionally, the chromosomal location of many micro-
satellites is known. This combination of variable size and
accurate mapping in relationship to genes of interest make
microsatellites ideal to study LOH. Microsatellites can also be
used to detect defective DNA mismatch repair. The DNA
mismatch repair system acts to repair slippage that occurs by
strand misalignment during DNA synthesis. Failure to do this
results in the addition or deletion of one or more repeat units
and a consequent change in microsatellite length.22 This can
be detected as a ‘‘band shift’’ in autoradiographs of amplified
DNA containing the mutated microsatellite. Tissues with
defective DNA mismatch repair demonstrate multiple band
shifts or microsatellite instability and are said to have a
‘‘mutator phenotype,’’ which, in hereditary nonpolyposis
colon cancer at least, allows the accumulation of mutations in
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tumor suppressor genes and oncogenes.23-25 In colorectal
cancer, there appears to be an inverse relationship between
defective DNA mismatch repair and LOH at other tumor
suppressor genes such as p53.26
We hypothesized that inactivation of the DNA mismatch
repair system might be mechanistically involved in the
evolution of HCC. We have recently demonstrated that
archival pathological tissues are excellent sources for the
study of genetic events involved in colorectal carcinogen-
esis.27 The use of microdissection and microsatellite allelotyp-
ing from multiple areas in individual tumors allows detection
of LOH and microsatellite instability from pathologically
defined tissues with a high degree of precision. The aim of
this study was to use this technique to determine the extent
and time of onset of microsatellite instability in premalignant
and malignant hepatic tissues, to determine the role and
timing of LOH of hMLH1 and hMSH2 gene loci in the
evolution of microsatellite instability, and to assess the
interaction between microsatellite instability and LOH at the
APC, p53, and DPC4 gene loci.
MATERIALS AND METHODS
Paraffin-embedded specimens of HCC were obtained from the
Department of Pathology, University of Michigan Medical Center,
and the Ann Arbor Veterans Affairs Medical Center. All tissue was
reviewed and graded28 by one pathologist (H.D.A.) who was blinded
to the results of the genetic analyses. Forty-five HCCs and one
adenoma from 44 patients were studied, including 28 surgical
resection specimens, 11 liver transplant explants, and 7 needle
biopsies. Two patients had fibrolamellar HCCs resected twice. In
both cases, the initial resection preceded the second by 2 years, and
the initial resection margins were clear of tumor.
Twenty-seven patients had cirrhosis. This was caused by alcohol
abuse alone in 8, alcohol combined with chronic hepatitis C in 4,
alcohol and chronic hepatitis B in 1, chronic hepatitis B in 4, chronic
hepatitis C in 3, and 1 patient each had Alagille’s syndrome,
a1-antitrypsin deficiency, primary biliary cirrhosis, and primary
sclerosing cholangitis. Three patients had cryptogenic cirrhosis and
these 3, along with 7 other patients with cirrhosis and 9 patients
without cirrhosis, had HCC diagnosed before the availability of
hepatitis C antibody testing. Four patients had insufficient nonma-
lignant liver tissue available to make or exclude a diagnosis of
cirrhosis. The remaining 13 patients included 3 with chronic
hepatitis (1 each with chronic hepatitis B and C, the other with no
viral serological testing), 2 patients with steatosis or steatohepatitis
caused by alcohol, and 8 with histologically normal liver. The 8
patients whose nonmalignant liver was histologically normal had no
recognized risk factors for HCC, although only 6 had hepatitis B
serology and only 1 had hepatitis C serology available. Details of
patient age and sex, liver histology, tumor size, and serum a-fetopro-
tein are presented in Table 1.
DNA was extracted from microdissected 5-µm sections of formalin-
fixed, paraffin-embedded tissues using previously reported tech-
niques.27 One section was stained with hematoxylin-eosin. This
reference slide was used to select areas for microdissection. An
unstained adjacent section was mounted on a glass slide, partially
deparaffinized by immersion in 20% xylene (diluted in absolute
ethanol) for 5 seconds, lightly stained with hematoxylin-eosin, and
superimposed upon the reference hematoxylin-eosin-stained sec-
tions. Pathologically identifiable target microdomains were removed
using a scalpel blade and a dissecting microscope (Fig. 1). With
experience, tissues could be removed by hand from either side of the
transition between nonmalignant and malignant liver tissue. Up to
nine areas, or microdomains, were microdissected from malignant
tissue in each HCC (median 3; total 169 domains). Multiple
domains were also studied from nonmalignant tissue (1 to 5
microdomains per case; median, 2; total 90 areas) to provide
reference tissue for genetic informativity and to test for LOH in
premalignant tissue. Each microdomain studied was histologically
uniform and varied in size from 1.5 mm to 13 mm in diameter. The
number and size of areas studied depended on both the amount of
tissue available and histological diversity within the tumor.
The microdissected tissue was deparaffinized and desiccated
before treatment with 15 µL of Genereleaser (BioVentures Inc.,
Murfreesboro, TN) according to the manufacturer’s instructions.
The samples were then made up to a final volume of 40 µL with 25
µL of digestion buffer (50 mmol/L Tris-HCl [pH 8.0]) containing
400 µg/mL proteinase K (Sigma, St. Louis, MO). Samples were
incubated for at least 72 hours at 55°C, and residual proteinase K
was inactivated by incubating at 95°C for 10 minutes.
The study strategy was to examine all areas with 16 microsatel-
lites linked to hMSH2, hMLH1, APC, p53, and DPC4 and to
correlate the pathological features with LOH at these loci. hMSH2
lies between D2S119 and D2S123 in a ,1.1-MB region bounded by
CA-5 and D2S391.18 hMSH2 also maps closely to CA-21, although
the precise location of this marker is not known.7 These five
microsatellites were used to study hMSH2. D3S1611 is located in an
intron of hMLH1, while the gene is ,1 cm centromeric to D3S1561.
D3S1277 lies between D3S1561 and D3S1611, and these three
microsatellites and D3S1029 were used to study hMLH1.29,30 An Alu
polymorphism in intron 1 of the p53 gene and D17S261 were used
to study LOH at p53.31,32 LOH at the APC gene was studied with
D5S346, located 30 to 70 kb downstream from APC and D5S107,
which is also located on 5q.33,34 LOH near DPC4 was examined
using D18S35, D18S46, and D18S65. Each microdissection pro-
vided enough DNA for 13 polymerase chain reactions (PCRs), and
DNA from two separate microdissections were required to test all 16
microsatellites.
DNA was amplified by PCR using 3 µL of template DNA solution
(from the tissue), 0.125 pmol of 58[32P] end-labeled forward primer,
0.125 pmol of the nonlabeled reverse primer, 200 µmol/L each of
dATP, dTTP, dCTP, and dGTP, and 0.25 units of Taq DNA polymerase
(Gibco, Gaithersburg, MD) in a final reaction volume of 5 mL. PCR
was performed for 35 to 40 cycles using optimal annealing tempera-
tures determined for each set of primers, ranging from 54°C to 60°C.
The amplified products were detected by autoradiography after
electrophoresis in an 8% polyacrylamide gel containing 7.5 mol/L
urea, 44.5 mmol/L Tris-borate (pH 8.3), and 1 mmol/L ethylenedi-
aminetetraacetic acid.
The gels were scanned at .300 dpi and analyzed using NIH
Image 1.57 (public domain software) to calculate the relative
intensity of bands from each microdomain. Informative normal
tissues were defined as those with two amplified bands on the














n 44 8 36
Age 52.1 (17.8) 54.8 (15.8) 51.0 (18.4) NS
Sex (Male/Female) 26/18 3/5 23/13 NS
Cirrhosis (Yes/No) 27/13* 5/3 22/10* NS
Fibrolamellar variant 8 1 7 NS
HCC Size (cm) 8.2 (6.3) 15.1 (8.7) 6.9 (4.9) .04
Serum a-fetoprotein† 44,804 (157,973) 517 (643) 54,276 (173,129) .11
Chronic viral
hepatitis 14 3 11 NS
*Four patients had insufficient nonmalignant liver tissue available to make
or exclude a diagnosis of cirrhosis.
†Normal value for a-fetoprotein is ,3.8 IU/µL.
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autoradiographs, usually separated by 2 to 8 base pairs. LOH was
suspected when the normal tissue was informative and there was a
reduction in relative intensity of $70% of one allele. Areas with
$70% reduction of relative intensity of one allele in the initial PCR
were restudied so that LOH could be confirmed with at least two
separate PCR amplifications. DNA for these two PCRs was usually
from different microdissections. An HCC had LOH if any microdo-
main fulfilled criteria for diagnosis. A band shift was defined as the
appearance of a new band on the autoradiograph, usually an
increase or decrease in size of 2 to 8 base pairs, representing a novel
PCR product. If there was more than one nonmalignant microdo-
main studied and LOH or band shifts appeared to be present in one
or more of these areas, multiple PCR from multiple sections was
performed to determine the consensus pattern of bands.
Unfortunately, there is no gold standard for the diagnosis of
microsatellite instability with respect to the number of band shifts
required. The number of band shifts detected will depend on the
DNA mismatch repair status, number and type of microsatellites
studied, and the number of areas studied. A variable number of
microdomains was microdissected for each case. To provide a
measure of the degree of microsatellite instability for each HCC, the
average number of band shifts/microdomain of HCC studied was
calculated for each tumor. The total number of band shifts from the
first PCR amplification of all microsatellites was used as the
numerator, and the number of areas of HCC studied for a case was
used as the denominator. An average of $1.0 band shift per
malignant microdomain was considered evidence of defective DNA
mismatch repair.9,22,23,35
Statistics for discrete variables were calculated by the x2 test or
Fisher’s Exact test and for continuous variables by the Student’s t test
assuming unequal variances. The study had the approval of both
hospitals’ Institutional Review Boards.
RESULTS
LOH of microsatellites linked to mismatch repair genes
occurred in 9 of 46 (19.6%) tumors studied (Table 2). Two of
these were fibrolamellar HCCs resected from the same patient
2 years apart, and they had identical patterns of microsatellite
loss. All 9 had LOH at microsatellites linked to hMLH1, and 6
also had LOH at hMSH2 gene loci. LOH of mismatch repair
gene loci was unrelated to the underlying liver pathology. The
clinical correlates of LOH of mismatch repair gene loci are
presented in Table 1, while Figs. 1 and 2 show the typical
appearance of autoradiographs of PCR-amplified microsatel-
lites.
In 26 cases, more than one nonmalignant microdomain
was studied. Unexpectedly and of particular importance,
LOH of hMSH2 and/or hMLH1 gene loci occurred in the
nonmalignant liver of 4 (15.4%) of these 26 cases, always in
association with LOH of hMSH2 and/or hMLH1 gene loci in
adjacent HCC. The histology of these four areas included two
areas of cirrhotic but non-neoplastic liver, a dysplastic
nodule, and an area with chronic hepatitis (no viral serology
available) adjacent to the hepatic adenoma. In 2 of these 4
cases, the chromosome lost in nonmalignant tissue was the
same as that lost in the HCC.
Within each HCC, not all microdomains fulfilled criteria
for LOH; however, the pattern of allelic loss was uniform
throughout multiple microdomains in each cancer, with a
single exception. In this HCC (case 9), two of seven
malignant microdomains had evidence of loss of alleles from
FIG. 1. Microdissection and determination of LOH (Case 34).
(A) Reference slide marked for microdissection. (B) Adjacent section
stained after microdissection. (C) Histology of microdomains marked
1 to 4 on reference slide: microdomain 1, Grade 2 trabecular HCC;
microdomain 2, normal liver; microdomain 3, normal liver; microdo-
main 4, Grade 2 trabecular HCC. (D) PCR product for hMSH2-
linked microsatellites are listed. Each lane corresponds to amplified
DNA from the microdomain of the same number in (A). Vertical
black arrows indicate bands with $70% reduction in relative
intensity compared with nonmalignant tissue (lanes 2 and 3). This
HCC had LOH of hMSH2 gene loci.
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one chromosome, while the other microdomains had evi-
dence of loss of the alleles from the other chromosome. The
picture in nonmalignant tissue with LOH of mismatch repair
genes was chaotic by comparison with allelic heterogeneity
occurring between adjacent microdomains from the same
section and DNA extracted from the same area, but from a
serial section.
LOH of tumor suppressor genes occurred in two cases with
LOH of mismatch repair gene loci, and seven with intact
mismatch repair genes (Table 3). LOH of the APC gene loci
appeared more frequently in tumors with LOH of hMSH2
and/or hMLH1 gene loci (P 5 .03) than in HCCs without
LOH at these loci, although the numbers are small in both
groups. An additional four tumors with LOH of mismatch
repair gene loci had probable LOH of APC that could not be
confirmed because of insufficient tissue. However, there was
no significant difference between HCCs with or without LOH
at mismatch repair gene loci with respect to LOH at p53,
DPC4, or at any combination of tumor suppressor genes.
Sixteen cases (34.8% of HCCs) had evidence of defective
DNA mismatch repair with $1.0 band shifts per malignant
microdomain. In the tumors with LOH of hMSH2 and/or
hMLH1 gene loci, the range for the number of band shifts per
microdomain of HCC studied was 0.77 to 2.33 (Fig. 3). Eight
of these nine had .1.0 band shift per microdomain. For
HCCs without LOH of mismatch repair gene loci, the average
was ,1.0 (P , .0001 when groups with and without LOH of
mismatch repair gene loci were compared). Having noted
this, 8 of the 37 cases without LOH of mismatch repair gene
loci had $1.0 band shift per malignant microdomain.
Microsatellite instability was also found in nonmalignant
liver tissue in 12 cases. Four of these 12 cases had LOH of
DNA mismatch repair gene loci in nonmalignant liver tissue,
and in nonmalignant areas they had between two and four
band shifts in the 16 microsatellites studied. A further 3 of
these 12 cases had LOH of mismatch repair gene loci in the
HCC, but not in the nonmalignant tissue. These three cases
each had nonmalignant areas with two band shifts. None of
the remaining 5 cases had LOH of mismatch repair loci in the
cancer or adjacent nonmalignant tissue. Three of these 5
cases had one band shift, a regenerative nodule had two band
shifts, and a dysplastic nodule had four band shifts present.
DISCUSSION
Microsatellite instability is a marker of defective DNA
mismatch repair and was present in one third of our HCCs
(34.8%). Microsatellite instability was strongly linked to LOH
of DNA mismatch repair gene loci. The appearance of
microsatellite instability in our HCCs with LOH of mismatch
repair gene loci suggests that mismatch repair function has
been compromised. LOH of hMLH1 and/or hMSH2 gene loci
also occurred in nonmalignant liver tissue adjacent to HCC in
4 of the 9 tumors with LOH of these loci. The likelihood that
LOH of mismatch repair gene loci in nonmalignant liver and
adjacent to HCCs are unrelated is P , .0005.
If criteria for microsatellite instability similar to ours are
used, microsatellite instability is more prevalent in HCCs
than in other sporadic malignancies (where it typically affects
,25% of cases).36 The degree of microsatellite instability we
detected in association with LOH of mismatch repair gene
loci (0.77 to 2.33 band shifts/ area of HCC) was not as great as
that seen in hereditary nonpolyposis colon cancer cancers,23
in which both copies of relevant genes are inactivated.37,38 In
malignancies from patients with hereditary nonpolyposis
colon cancer, values of $4 band shifts per area of cancer
would be expected using our markers. However, the degree of
microsatellite instability we detected in HCCs is similar to
that seen in some sporadic colorectal cancers.36,39
It was not possible to determine whether LOH of hMSH2
or hMLH1 gene loci preceded the onset of microsatellite
instability, although clearly both events may occur before
malignant transformation. However, it is likely that LOH of
mismatch repair gene loci in HCC usually occurs before the
emergence of the malignant clone. If LOH of mismatch repair
genes occurred after malignant transformation, it would be
expected to have a heterogeneous distribution throughout
the tumor, with LOH randomly affecting either parental
chromosome. However, in 8 of 9 cases, there was a uniform
pattern of LOH in different regions of the tumor, indicating
that the same chromosome was lost throughout the cancer.
By comparison, the pattern of hMSH2 and hMLH1 loss in
premalignant liver tissue was chaotic. This highly variable
pattern of mismatch repair gene loss detected in some
premalignant liver tissues is probably caused by the presence
of multiple tiny clones within the premalignant tissues, and
our findings are analogous to the disordered pattern of allelic
loss of p53-linked microsatellites in colonic adenomas with
high-grade dysplasia and the stable pattern of p53 loss found
in the cancer arising from these adenomas.27 These data
suggest that there may be selective pressure for LOH of
hMLH1 and/or hMSH2 during malignant transformation in a
subset of HCCs.
Detecting LOH in cirrhotic liver and particularly in noncir-
rhotic liver was somewhat unexpected. Since the commence-
TABLE 2. Pattern of LOH* of hMSH2, hMLH1, APC, p53,









10† HCC * *
14† HCC * *
18 HCC *
19 HCC *




33 HCC * * *
34 HCC * *
39 HCC * *




Chronic hepatitis * * *
Total LOH (%) 6 (13.0%) 9 (19.6%) 3 (6.5%) 6 (13.0%) 2 (4.4%)
*LOH of a gene loci. Cases not shown had no LOH detected.
†Fibrolamellar HCCs resected from same patient 2 years apart. Initial
resection margins were clear with no clinical evidence of residual disease at
time of first operation.
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ment of this study, two groups have reported LOH in cirrhotic
liver, at 8p21.3-2240 and the mannose-6-phosphate/insulin-
like growth factor II receptor.41 The detection of LOH in an
area of chronic hepatitis adjacent to a tumor in one of our
cases is not without precedent, because LOH has recently
been described in histologically normal tissues adjacent to
breast cancers.42 Our findings add strength to previous
observations that premalignant genetic changes can occur in
cirrhotic liver.








Repair Gene Loci P
LOH of APC 3 2 1 .03
LOH of p53 6 1 5 NS
LOH of DCC 2 0 2 NS
LOH of APC and/or
p53 and/or DCC 9 2 7 NS
A B
C
FIG. 2. Interpretation of LOH and
band shifts: * $70% reduction in
relative band intensity; black arrow:
band shift. Case 41 was from a
56-year-old woman with cirrhosis
caused by a1-antitrypsin deficiency.
(A) Cirrhotic nodule adjacent to
HCC (original magnification 3165)
(DNA from this area gave results
seen below in [C], lane 10). (B) Photo-
micrograph of HCC (original magni-
fication 3165). (C) PCR product.
Lanes 1 to 3 and lane 10 are from
cirrhotic liver, while lanes 4 to 9 are
from the HCC. Compared with cir-
rhotic liver in lanes 1 to 3, there is a
$70% reduction in relative band
intensity of the larger allele of the
hMSH2-linked microsatellite D2S119
in lanes 5 and 8, from the HCC, and
in lane 10 from a cirrhotic nodule
adjacent to the HCC. For CA-5
(linked to hMSH2), there is LOH in
lanes 7, 8, and 10, while lane 9 shows
a band shift, and, as discussed in the
text, cannot be considered to show
LOH. D2S391 is also linked to
hMSH2 and shows loss in lanes 8, 9,
and 10. For all these microsatellites,
the allele lost in the HCC was the
opposite allele to that lost in lane 10,
from a cirrhotic nodule. This indi-
cates that LOH affected different
chromosomes in the HCC and in
microdomain 10. D3S1561, linked
to hMLH1, shows evidence of LOH
in the HCC, lane 6. Lane 9 shows
another band shift, while there is
also evidence of band shifts in lane
3, from cirrhotic tissue.
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This study had a significant number of HCCs arising in
noncirrhotic liver tissue. In large necropsy series, HCCs are
present in approximately 17% of patients with cirrhosis,
while for noncirrhotic patients, the prevalence is between
0.11% and 0.30%.43,44 Because of the relative prevalence of
cirrhosis in these necropsy series, HCC is approximately
three times more likely to be found in conjunction with
cirrhosis than without cirrhosis, although clearly it does
occur in both settings. Part of the reason for the relative
excess of noncirrhotic patients in our study population is
likely to be due to where tissues were obtained for study.
Twenty-eight of our cases were from surgical resections and,
as a consequence of selection criteria for surgery, less likely to
have advanced liver disease.
A criticism of studying DNA extracted from microdissected
formalin-fixed tissues is that the DNA concentration is very
low (,10 ng/mL) and there is a risk of PCR amplification of
one or other alleles because of limiting concentration of DNA
template in the PCR reactions. This could give the false
impression of LOH. We were concerned about this possibility
and for this reason used criteria for LOH that were much
stricter than previous studies.45-47 The uniform pattern of
LOH of hMLH1 and/or hMSH2 gene loci throughout most
affected HCCs and the fact that LOH events predominately
involved mismatch repair genes rather than the tumor
suppressor gene loci argues against amplification of one or
other alleles due to low initial DNA concentration. PCR may
amplify small alleles in favor of large alleles (so-called
preferential amplification). If this occurred, it would give the
impression of LOH affecting the larger microsatellite alleles.
However, as seen in Fig. 2, both the larger and smaller
microsatellite alleles were affected by LOH, and preferential
amplification seems a theoretical concern rather than a real
issue.48
It is possible that LOH of mismatch repair genes and
defective DNA mismatch repair is more prevalent than we
determined for several reasons. Although microdissection
allows DNA extraction from a microdomain of ‘‘pure’’ malig-
nant cells, admixture of nonmalignant connective tissue,
hematopoietic and hepatic cells within and at the margins of
malignant tissue can ‘‘dilute’’ LOH. Additionally, if microsatel-
lite alleles vary in size by only two or four base pairs, bands
and shadow bands can overlap, making quantitation of LOH
difficult, while if a band shift is present, LOH cannot be
diagnosed because the allele giving rise to the band shift
cannot be determined with certainty. As a consequence of
these technical issues, the initial microsatellite amplifications
may have not correctly identified tumors with LOH.
There are two further reasons why this study may have
underdiagnosed the prevalence of LOH of mismatch repair
genes and microsatellite instability in HCC. A variety of
mismatch repair genes have been identified in humans, and at
least four—hMSH2, GTBP, hMLH1, and hPMS2—appear
necessary for effective mismatch repair, while only loci
known to be linked to hMSH2 and hMLH1 were studied,
because these are the mismatch repair genes most frequently
affected in hereditary nonpolyposis colon cancer.14,15 LOH
could affect GTBP, hPMS2, and additional genetic loci that
encode for proteins required for DNA mismatch repair and
would not have been detected by this study. Second, all but
one of the microsatellites studied were CA repeats. Cell lines
with inactivating mutations in hMSH2, hMLH1, and hPMS2
show microsatellite instability for CA repeats. However, cell
lines deficient in GTBP and another mismatch repair enzyme,
DNA polymerase d, do not and so functional loss of these
proteins would not necessarily be detected by this study.14,49
The association of LOH of DNA mismatch repair genes loci
and microsatellite instability is unusual but has been previ-
ously reported in two circumstances. Microsatellite instability
and LOH at the hMLH1 locus on 3p21—findings similar to
this study—has been reported in non-small cell lung carcino-
mas,50 while Parsons et al.51 described microsatellite instabil-
ity in lymphocytes from some but not all patients with
hereditary nonpolyposis colon cancer caused by mutations of
DNA mismatch repair genes. They showed heterogeneity of
microsatellite changes in these lymphocytes and that these
changes were only apparent when DNA from a small number
of cells was analyzed (as in our study). They were able to
show deficient DNA mismatch repair activity in extracts from
these cells, even though they could not show mutation in the
remaining intact copy of the mismatch repair gene, or
mutations in other known mismatch repair genes or evidence
of inhibition of repair by the mutated gene product in mixing
experiments. This implies an effect of haploinsufficiency but
does not explain why this is not more widely seen.
More difficult to explain is why loss should affect two
mismatch repair gene loci. Two groups have shown that when
microsatellite instability is present, DNA repair genes them-
selves become targets for inactivation.52,53 Cells with a
mutator phenotype may have a selective growth advantage if
other DNA repair systems are inactivated. A similar series of
events may be occurring in HCCs. Although numbers are
small, all HCCs with LOH of hMSH2 gene loci also had LOH
FIG. 3. Histogram of band shifts per domain of HCC. Band shifts per
domain of HCC is an average calculated by dividing the total number of band
shifts from the initial amplification of all 16 microsatellites for all malignant
microdomains studied from an HCC, by the number of microdomains
studied. LOH mismatch repair genes: the 9 tumors that fulfilled the criteria
for diagnosis of LOH of hMSH2 and/or hMLH1 gene loci. No LOH of
mismatch repair genes: remaining 37 HCCs. The presence of band shifts was
significantly associated with LOH of mismatch repair gene loci (P , .0001),
when the 9 tumors with LOH of mismatch repair gene loci were compared
with 37 HCCs that did not reach criteria for diagnosis of LOH.
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of hMLH1 loci. Once LOH of one of these gene loci occurs,
there may be selective pressure on loss of other DNA repair
genes with progressive impairment of components of the
mismatch repair system.
We can only speculate on the growth advantage related to
the loss of mismatch repair competency in HCCs. DNA
mismatch repair has been shown to interact with other DNA
repair systems such as O6-methylguanine methyltransferase
(O6-MT).54 O6-methylguanine is the major mutagen pro-
duced by DNA alkylation54 and is not directly cytotoxic, but
results in G-to-A transitions at affected bases. O6-MT removes
the abnormal methyl group. Cell lines deficient in O6-MT
must inactivate mismatch repair to proliferate, presumably
because mismatch repair proficient cells can detect O6-
methylguanine and induce cell cycle arrest at the G2 check-
point.55 O6-MT activity is reduced in cirrhotic liver,56 and it is
possible that loss of mismatch repair function in O6-MT-
deficient tissues may offer a selective growth advantage to an
evolving premalignant clone. Another potential growth advan-
tage related to microsatellite instability is that cells with
defective DNA mismatch repair have a mutable phenotype
and do not ‘‘require’’ LOH to inactivate tumor suppressor
genes that limit malignant growth.
In summary, there appears to be a selective pressure for
LOH of the DNA mismatch repair genes, hMLH1 and
hMSH2, during the evolution of a subset of HCCs. This loss
appears to occur before the emergence of the malignant clone
and is accompanied by microsatellite instability, suggesting a
role in hepatic carcinogenesis. Taken together, our findings
confirm the malignant potential of cirrhotic liver and demon-
strate that significant genomic injury can be present in
histologically normal liver. The factors that predispose to
LOH of mismatch repair genes and microsatellite instability,
the relationship of these changes to malignant transforma-
tion, and their clinical significance are not clear and warrant
further study.
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